Global Alcohol Addiction Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Alcohol Addiction treatment during 2019. Clinical development activities are being undertaken by more than 30 companies including AbbVie Inc, Adial Pharmaceuticals LLC, Amygdala Neurosciences Inc, Arbor Pharmaceuticals LLC, Assuage Pharmaceuticals Inc and others.
A Significant contribution to the Alcohol Addiction pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Alcohol Addiction pipeline included 33 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Alcohol Addiction condition and increased access to investments is encouraging growth of Alcohol Addiction drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Alcohol Addiction drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Alcohol Addiction therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Alcohol Addiction pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Alcohol Addiction. Further, orphan drug status, fast track designation, grants awarded and other special status for Alcohol Addiction pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Alcohol Addiction pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Alcohol Addiction Pipeline candidates-
A Significant contribution to the Alcohol Addiction pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Alcohol Addiction pipeline included 33 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Alcohol Addiction condition and increased access to investments is encouraging growth of Alcohol Addiction drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Alcohol Addiction drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Alcohol Addiction therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Alcohol Addiction pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Alcohol Addiction. Further, orphan drug status, fast track designation, grants awarded and other special status for Alcohol Addiction pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Alcohol Addiction pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Alcohol Addiction Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Alcohol Addiction drugs
- Late phase: Phase 3 and in-approval Alcohol Addiction drugs
- Company overview
- Snapshot
- Alcohol Addiction therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Alcohol Addiction- Disease Overview
2.2 Alcohol Addiction- Pipeline Snapshot
2.3 Alcohol Addiction- Pipeline Drugs by Phase
2.4 Alcohol Addiction- Pipeline Drugs by Company
2.5 Alcohol Addiction- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 AbbVie Inc Alcohol Addiction Drug Pipeline, H2- 2019
3.2 Adial Pharmaceuticals LLC Alcohol Addiction Drug Pipeline, H2- 2019
3.3 Amygdala Neurosciences Inc Alcohol Addiction Drug Pipeline, H2- 2019
3.4 Arbor Pharmaceuticals LLC Alcohol Addiction Drug Pipeline, H2- 2019
3.5 Assuage Pharmaceuticals Inc Alcohol Addiction Drug Pipeline, H2- 2019
3.6 Astraea Therapeutics LLC Alcohol Addiction Drug Pipeline, H2- 2019
3.7 AstraZeneca Plc Alcohol Addiction Drug Pipeline, H2- 2019
3.8 BioCorRx Inc Alcohol Addiction Drug Pipeline, H2- 2019
3.9 Bioprojet SCR Alcohol Addiction Drug Pipeline, H2- 2019
3.10 Chronos Therapeutics Ltd Alcohol Addiction Drug Pipeline, H2- 2019
3.11 Confluence Pharmaceuticals LLC Alcohol Addiction Drug Pipeline, H2- 2019
3.12 Corcept Therapeutics Inc Alcohol Addiction Drug Pipeline, H2- 2019
3.13 Curemark LLC Alcohol Addiction Drug Pipeline, H2- 2019
3.14 EpiVario Inc Alcohol Addiction Drug Pipeline, H2- 2019
3.15 Ethypharm SA Alcohol Addiction Drug Pipeline, H2- 2019
3.16 Kinnov Therapeutics SAS Alcohol Addiction Drug Pipeline, H2- 2019
3.17 Kinoxis Therapeutics Pty Ltd Alcohol Addiction Drug Pipeline, H2- 2019
3.18 Kyorin Pharmaceutical Co Ltd Alcohol Addiction Drug Pipeline, H2- 2019
3.19 Laboratorio Farmaceutico CT Srl Alcohol Addiction Drug Pipeline, H2- 2019
3.20 Mapreg SAS Alcohol Addiction Drug Pipeline, H2- 2019
3.21 Montisera Ltd Alcohol Addiction Drug Pipeline, H2- 2019
3.22 Omeros Corp Alcohol Addiction Drug Pipeline, H2- 2019
3.23 Opiant Pharmaceuticals Inc Alcohol Addiction Drug Pipeline, H2- 2019
3.24 Osmotica Pharmaceutical Corp Alcohol Addiction Drug Pipeline, H2- 2019
3.25 Pop Test Oncology LLC Alcohol Addiction Drug Pipeline, H2- 2019
3.26 Savant HWP Inc Alcohol Addiction Drug Pipeline, H2- 2019
3.27 Silence Therapeutics Plc Alcohol Addiction Drug Pipeline, H2- 2019
3.28 SK Biopharmaceuticals Co Ltd Alcohol Addiction Drug Pipeline, H2- 2019
3.29 Sosei Heptares Alcohol Addiction Drug Pipeline, H2- 2019
3.30 Syntropharma Ltd Alcohol Addiction Drug Pipeline, H2- 2019
3.31 Tonix Pharmaceuticals Holding Corp Alcohol Addiction Drug Pipeline, H2- 2019
3.32 VM Discovery Inc Alcohol Addiction Drug Pipeline, H2- 2019
3.33 Zynerba Pharmaceuticals Inc Alcohol Addiction Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Alcohol Addiction- Phase 1 Drug Details
4.2 Alcohol Addiction- Phase 1 Drug Overview
4.3 Alcohol Addiction- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Alcohol Addiction- Phase 2 Drug Details
5.2 Alcohol Addiction- Phase 2 Drug Overview
5.3 Alcohol Addiction- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Alcohol Addiction- Phase 3 Drug Details
6.2 Alcohol Addiction- Phase 3 Drug Overview
6.3 Alcohol Addiction- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Alcohol Addiction- Pre-clinical Phase Drug Details
7.2 Alcohol Addiction- Pre-clinical Phase Drug Overview
7.3 Alcohol Addiction- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Alcohol Addiction- Disease Overview
2.2 Alcohol Addiction- Pipeline Snapshot
2.3 Alcohol Addiction- Pipeline Drugs by Phase
2.4 Alcohol Addiction- Pipeline Drugs by Company
2.5 Alcohol Addiction- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 AbbVie Inc Alcohol Addiction Drug Pipeline, H2- 2019
3.2 Adial Pharmaceuticals LLC Alcohol Addiction Drug Pipeline, H2- 2019
3.3 Amygdala Neurosciences Inc Alcohol Addiction Drug Pipeline, H2- 2019
3.4 Arbor Pharmaceuticals LLC Alcohol Addiction Drug Pipeline, H2- 2019
3.5 Assuage Pharmaceuticals Inc Alcohol Addiction Drug Pipeline, H2- 2019
3.6 Astraea Therapeutics LLC Alcohol Addiction Drug Pipeline, H2- 2019
3.7 AstraZeneca Plc Alcohol Addiction Drug Pipeline, H2- 2019
3.8 BioCorRx Inc Alcohol Addiction Drug Pipeline, H2- 2019
3.9 Bioprojet SCR Alcohol Addiction Drug Pipeline, H2- 2019
3.10 Chronos Therapeutics Ltd Alcohol Addiction Drug Pipeline, H2- 2019
3.11 Confluence Pharmaceuticals LLC Alcohol Addiction Drug Pipeline, H2- 2019
3.12 Corcept Therapeutics Inc Alcohol Addiction Drug Pipeline, H2- 2019
3.13 Curemark LLC Alcohol Addiction Drug Pipeline, H2- 2019
3.14 EpiVario Inc Alcohol Addiction Drug Pipeline, H2- 2019
3.15 Ethypharm SA Alcohol Addiction Drug Pipeline, H2- 2019
3.16 Kinnov Therapeutics SAS Alcohol Addiction Drug Pipeline, H2- 2019
3.17 Kinoxis Therapeutics Pty Ltd Alcohol Addiction Drug Pipeline, H2- 2019
3.18 Kyorin Pharmaceutical Co Ltd Alcohol Addiction Drug Pipeline, H2- 2019
3.19 Laboratorio Farmaceutico CT Srl Alcohol Addiction Drug Pipeline, H2- 2019
3.20 Mapreg SAS Alcohol Addiction Drug Pipeline, H2- 2019
3.21 Montisera Ltd Alcohol Addiction Drug Pipeline, H2- 2019
3.22 Omeros Corp Alcohol Addiction Drug Pipeline, H2- 2019
3.23 Opiant Pharmaceuticals Inc Alcohol Addiction Drug Pipeline, H2- 2019
3.24 Osmotica Pharmaceutical Corp Alcohol Addiction Drug Pipeline, H2- 2019
3.25 Pop Test Oncology LLC Alcohol Addiction Drug Pipeline, H2- 2019
3.26 Savant HWP Inc Alcohol Addiction Drug Pipeline, H2- 2019
3.27 Silence Therapeutics Plc Alcohol Addiction Drug Pipeline, H2- 2019
3.28 SK Biopharmaceuticals Co Ltd Alcohol Addiction Drug Pipeline, H2- 2019
3.29 Sosei Heptares Alcohol Addiction Drug Pipeline, H2- 2019
3.30 Syntropharma Ltd Alcohol Addiction Drug Pipeline, H2- 2019
3.31 Tonix Pharmaceuticals Holding Corp Alcohol Addiction Drug Pipeline, H2- 2019
3.32 VM Discovery Inc Alcohol Addiction Drug Pipeline, H2- 2019
3.33 Zynerba Pharmaceuticals Inc Alcohol Addiction Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Alcohol Addiction- Phase 1 Drug Details
4.2 Alcohol Addiction- Phase 1 Drug Overview
4.3 Alcohol Addiction- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Alcohol Addiction- Phase 2 Drug Details
5.2 Alcohol Addiction- Phase 2 Drug Overview
5.3 Alcohol Addiction- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Alcohol Addiction- Phase 3 Drug Details
6.2 Alcohol Addiction- Phase 3 Drug Overview
6.3 Alcohol Addiction- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Alcohol Addiction- Pre-clinical Phase Drug Details
7.2 Alcohol Addiction- Pre-clinical Phase Drug Overview
7.3 Alcohol Addiction- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
